07.14.15
Headquarters: Osaka, Japan
twitter.com/TakedaPharmaDe
www.takeda.com
Top Selling Drugs
Takeda faced some difficulties in 2014, when a federal jury in Lafayette, LA reached a verdict in a lawsuit accusing Takeda of failing to warn users about research that linked the diabetes drug Actos to an increased risk of bladder cancer. Takeda was ordered to pay $6 billion in punitive damages and its partner Eli Lilly & Co. was ordered to pay $3 billion. Takeda and Lilly are contesting the verdict hoping that the fines will be reduced. Takeda developed and manufactured Actos and Lilly marketed the drug in the U.S. and Canada.
However, during the year, Takeda took steps to improve its situation and implemented strategies to boost R&D productivity. In the cardiovascular and metabolic area, Takeda filed a New Drug Application (NDA) in Japan for the once-weekly type 2 diabetes treatment SYR-472 (trelagliptin). In oncology, it obtained NDA approval in Japan for Adcetris (brentuximab vedotin) for the treatment of malignant lymphoma. In the central nervous system area, marketing authorization was granted by the European Commission for atypical antipsychotic Latuda (lurasidone) for the treatment of schizophrenia. In vaccines, Takeda obtained NDA approval in Japan for cell-cultured influenza vaccine H5N1 “TAKEDA” 1mL and cell-cultured influenza vaccine (prototype*4) “TAKEDA” 1mL for the prevention of pandemic influenza to be manufactured in the company’s Hikari Plant.
Some notable events during the year included an R&D alliance between GE Healthcare and Takeda to develop drugs as well as new diagnostic technologies targeting liver disease. Mersana Therapeutics and Takeda expanded their ongoing collaboration to create Fleximer antibody-drug conjugate (ADC) drug candidates to include additional oncology targets.
Also, Takeda opened its new office in Biopolis, Singapore. The expanded space will consolidate Singapore operations and serve as the Emerging Markets Business Unit headquarters, Takeda’s Development Center Asia, and the company’s Vaccine Business Unit.
twitter.com/TakedaPharmaDe
www.takeda.com
Headcount: | 31,328 | |
Year Established: | 1781 | |
Revenues: | $16,424 | (flat) |
Net Income: | $1,064 | (flat) |
R&D: | $3,316 | (-1%) |
Top Selling Drugs
Drug | Indication | 2014 Sales | (+/-%) |
Velcade | multiple myeloma | $1,276 | 21% |
Candesartan | hypertension | $1,051 | -31% |
Leuprorelin | cancer | $1,036 | -3% |
Pantoprazole | peptic ulcer | $867 | 0% |
Lansoprazole | peptic ulcer | $860 | -17% |
Takeda faced some difficulties in 2014, when a federal jury in Lafayette, LA reached a verdict in a lawsuit accusing Takeda of failing to warn users about research that linked the diabetes drug Actos to an increased risk of bladder cancer. Takeda was ordered to pay $6 billion in punitive damages and its partner Eli Lilly & Co. was ordered to pay $3 billion. Takeda and Lilly are contesting the verdict hoping that the fines will be reduced. Takeda developed and manufactured Actos and Lilly marketed the drug in the U.S. and Canada.
However, during the year, Takeda took steps to improve its situation and implemented strategies to boost R&D productivity. In the cardiovascular and metabolic area, Takeda filed a New Drug Application (NDA) in Japan for the once-weekly type 2 diabetes treatment SYR-472 (trelagliptin). In oncology, it obtained NDA approval in Japan for Adcetris (brentuximab vedotin) for the treatment of malignant lymphoma. In the central nervous system area, marketing authorization was granted by the European Commission for atypical antipsychotic Latuda (lurasidone) for the treatment of schizophrenia. In vaccines, Takeda obtained NDA approval in Japan for cell-cultured influenza vaccine H5N1 “TAKEDA” 1mL and cell-cultured influenza vaccine (prototype*4) “TAKEDA” 1mL for the prevention of pandemic influenza to be manufactured in the company’s Hikari Plant.
Some notable events during the year included an R&D alliance between GE Healthcare and Takeda to develop drugs as well as new diagnostic technologies targeting liver disease. Mersana Therapeutics and Takeda expanded their ongoing collaboration to create Fleximer antibody-drug conjugate (ADC) drug candidates to include additional oncology targets.
Also, Takeda opened its new office in Biopolis, Singapore. The expanded space will consolidate Singapore operations and serve as the Emerging Markets Business Unit headquarters, Takeda’s Development Center Asia, and the company’s Vaccine Business Unit.
The Japanese giant is still trying to steady its ship after a difficult time over the past few years, and with the new foreign CEO Christophe Weber in situ, it’s a whole new ball game. Pursuing oncology still seems to be its aim, but having acquired Millennium’s Alisertib it’s struggling to make things move as quickly as it would like as the Phase III lymphoma trials for the drug have failed to come through with positive results. They are now relying on ixazomib to follow in the footsteps of Velcade, which it hopes to submit to the FDA later this year for multiple myeloma. —Adele Graham-King |